Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Abstract

Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with <i>EGFR-</i>mutated metastatic NSCLC previously treated with EGFR TKIs. No new safety signals were identified.